What to Expect From Abbott Laboratories' Q2 2025 Earnings Report
/Abbott%20Laboratories%20HQ%20photo-%20by%20Sundry%20Photography%20via%20iStock.jpg)
With a market cap of $233.8 billion, Abbott Laboratories (ABT) is a global healthcare company that discovers, develops, manufactures, and sells a diverse range of healthcare products across diagnostics, medical devices, nutritionals, and branded generics in emerging markets. Abbott has grown through strategic acquisitions, such as St. Jude Medical and Alere Inc., while streamlining its portfolio through divestitures, including its developed markets generics and vision care businesses.
The North Chicago, Illinois-based company is slated to announce its fiscal Q2 2025 earnings results before the market opens on Thursday, July 17. Ahead of the event, analysts are expecting ABT to report an adjusted EPS of $1.25, up 9.7% from $1.14 in the year-ago quarter. The company has met or surpassed Wall Street's bottom-line estimates in the past four quarterly reports. In Q1 2025, Abbott exceeded the consensus adjusted EPS estimate by 1.9%.
For fiscal 2025, analysts expect the medical device maker to report adjusted EPS of $5.16, up 10.5% from $4.67 in fiscal 2024. Looking forward to fiscal 2026, adjusted EPS is expected to grow 9.9% year-over-year to $5.67.
Shares of ABT have surged 28.4% over the past 52 weeks, outperforming both the S&P 500 Index's ($SPX) 12.6% rise and the Health Care Select Sector SPDR Fund's (XLV) 8.2% decline over the same period.
Despite reporting weaker-than-expected Q1 2025 revenue of $10.4 billion, shares of Abbott Laboratories rose 2.8% on Apr. 16. The company reaffirmed its full-year 2025 profit forecast of $5.05 per share to $5.25 per share. Abbott also announced $500 million in new investments in manufacturing and R&D in Illinois and Texas, which are expected to mitigate the impact of U.S. tariffs estimated at around $300 million.
Additionally, stronger-than-expected Q1 adjusted EPS of $1.09, along with ongoing global production of high-demand products like the FreeStyle Libre, boosted investor sentiment.
Analysts' consensus rating on Abbott stock is bullish, with a "Strong Buy" rating overall. Among 26 analysts covering the stock, 18 recommend a "Strong Buy,” two have a "Moderate Buy" rating, and six give a "Hold" rating. This configuration is slightly more bullish than three months ago, with 17 analysts suggesting a "Strong Buy."
The average analyst price target for ABT is $143.65, indicating a potential upside of just 6.9% from the current levels.
On the date of publication, Sohini Mondal did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here.